NASDAQ$TMCI

Treace Medical Concepts Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Briefing

Treace Medical Concepts reported Q4 2025, revenue of $62.5M, net loss of $9.4M.

For Q4 2025, Treace Medical Concepts reported revenue of $62.5M, a net loss of $9.4M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.

  • Revenue $62.5M.
  • Net loss $9.4M.
  • Treace Medical Concepts MD&A covers liquidity, credit, and operating priorities.

Headline financials

Total Revenue

$62.5M

Previous: $68.7M-9.0%
EPS (adj)

-$0.15

Previous: -$0.01-1400.0%
Gross Margin

80.6%

Previous: 80.7%-0.1%
Adjusted EBITDA

$6.19M

Previous: $11.1M-44.3%
Granted Patents

135

No prior period
Pending Patent Applications

199

No prior period
Net Income

-$9.4M

Previous: -$501K-1776.2%
Operating Income

-$5.92M

Previous: -$204K-2802.9%
Gross Profit

$50.4M

Previous: $55.5M-9.1%

Revenue & EPS history

Treace · Revenue · Quarterly

$62.5M

Q4 2025-9%vs Q4 2024
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.

Tailwinds

  • MD&A highlights liquidity, capital, and core business trends.
  • Segment or product commentary supports the earnings narrative.

Headwinds

  • Macro, rates, or input costs may pressure near-term margins.
  • One-time items can affect year-over-year comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-5.8%

Avg return

Earnings day

-5.9%

Avg return

5 days after

-3.7%

Avg return

30 days after

33%

7 / 21 earnings

Positive

+43.3%

Q3 2024

Best reaction

-62.8%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.7%+31.8%+82.3%
Q4 2025-11.0%-30.0%-41.9%
Q3 2025-28.6%-46.6%-56.0%
Q1 2025-9.5%-10.9%-22.9%
Q4 2024-2.1%+0.0%-7.4%
Q3 2024+43.3%+48.1%+42.7%
Q2 2024+2.7%-8.5%-13.9%
Q1 2024-62.8%-60.9%-45.5%
Q4 2023-5.7%-6.4%-8.9%
Q3 2023-42.1%-32.0%-11.4%
Q2 2023-16.9%-20.3%-31.3%
Q1 2023-5.5%-4.9%-0.9%
Q4 2022+21.1%+19.0%+37.5%
Q3 2022+1.9%+16.1%+13.7%
Q2 2022-1.3%+1.0%+10.1%
Q1 2022-14.4%-30.2%-9.3%
Q4 2021-1.0%-7.4%-5.7%
Q3 2021-0.8%-6.6%-28.5%
Q2 2021-3.3%-5.9%-3.2%
Q4 2020+4.7%+14.9%+11.5%
Q1 2021+4.7%+14.9%+11.5%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro